List of adverse effects of nilotinib

This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence.[1][2][3][4][5][6]

Very common

edit

Very common (>10% incidence) adverse effects include:

Common

edit

Common (1–10% incidence) adverse effects include:

  • Constipation
  • Diarrhoea
  • Vomiting
  • Upper abdominal pain
  • Indigestion
  • Joint pain
  • Muscle spasms
  • Pain in extremities
  • Asthenia
  • Peripheral oedema
  • Folliculitis
  • Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
  • Skin papilloma
  • Eosinophilia
  • Lymphopenia
  • Insomnia
  • Anxiety
  • Depression
  • Diabetes mellitus
  • Hypercholesterolaemia
  • Hyperlipidaemia
  • Hypertriglyceridaemia
  • Hyperglycaemia
  • Loss of appetite
  • Dizziness
  • Hypoaesthesia
  • Peripheral neuropathy
  • Eye pruritus
  • Conjunctivitis
  • Dry eye (including xerophthalmia)
  • Vertigo
  • Flushing
  • Hypertension
  • Angina pectoris
  • Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
  • QT interval prolonged
  • Palpitations
  • Cough
  • Dyspnoea
  • Abdominal distension
  • Abdominal discomfort
  • Taste changes
  • Flatulence
  • Abnormal liver function
  • Bone pain
  • Back pain
  • Erythema
  • Hyperhidrosis
  • Contusion
  • Acne
  • Dermatitis (including allergic, exfoliative and acneiform)
  • Night sweats
  • Fever without an infectious cause
  • Chest pain (including non-cardiac chest pain)
  • Chest discomfort
  • Decreased haemoglobin
  • Increased blood amylase
  • Increased blood alkaline phosphatase
  • Gamma-glutamyltransferase increased
  • Weight increased
  • Increased blood insulin
  • Increased lipoprotein (including very low density and high density)

Uncommon

edit

Uncommon (0.1–1% incidence) adverse effects include:

References

edit
  1. ^ "Complete Nilotinib information from Drugs.com". Drugs.com. Retrieved 25 January 2014.
  2. ^ "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Retrieved 25 January 2014.
  3. ^ "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Retrieved 25 January 2014.
  4. ^ "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Retrieved 25 January 2014.
  5. ^ "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 25 January 2014.
  6. ^ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  7. ^ a b Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019: 3679319. doi:10.1155/2019/3679319. PMC 6875312. PMID 31781436.
  8. ^ Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220. S2CID 43118790.{{cite journal}}: CS1 maint: multiple names: authors list (link)